16:46 , Mar 16, 2018 |  BC Week In Review  |  Financial News

AI play BioXcel raises $60M IPO

Artificial intelligence company BioXcel Therapeutics Inc. (NASDAQ:BTAI) raised $60 million on March 8 through the sale of 5.5 million shares at $11 in an upsized IPO underwritten by Barclays, UBS, BMO and Canaccord Genuity. The...
19:25 , Mar 8, 2018 |  BC Extra  |  Financial News

AI play BioXcel raises $60M IPO

BioXcel Therapeutics Inc. (NASDAQ:BTAI) gained $0.03 to $11.03 Thursday after the artificial intelligence company raised $60 million through the sale of 5.5 million shares at $11 in an upsized IPO underwritten by Barclays, UBS, BMO...
16:26 , Jan 12, 2018 |  BC Week In Review  |  Company News

Shire to split neuro and rare disease businesses

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will split its neuroscience and rare disease businesses into two divisions. The separation comes after the pharma said in its 2Q17 earnings report that it was evaluating options for...
23:54 , Jan 9, 2018 |  BC Extra  |  Company News

Shire splits neuro and rare disease businesses

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will split its neuroscience and rare disease businesses into two divisions. The separation comes after the pharma said in its 2Q17 earnings report that it was evaluating options for...
19:58 , Aug 4, 2017 |  BC Week In Review  |  Company News

Shire evaluating neurology pipeline

In its 2Q17 earnings report, Shire plc (LSE:SHP; NASDAQ:SHPG) said it will evaluate options for its neurology franchise, with the potential of spinning out the company’s core ADHD business into an independent public company. The...
23:20 , Aug 3, 2017 |  BC Extra  |  Company News

Shire evaluating neurology pipeline

In its 2Q17 earnings report, Shire plc (LSE:SHP; NASDAQ:SHPG) said it will evaluate options for its neurology franchise, with the potential of spinning out the company’s core ADHD business into an independent public company. The...
15:02 , Jun 2, 2017 |  BC Week In Review  |  Company News

Shionogi launches ADHD drug Intuniv in Japan

Shionogi & Co. Ltd. (Tokyo:4507) launched Intuniv guanfacine in Japan to treat pediatric ADHD. The Japanese National Health Insurance (NHI) list price of the once-daily adrenergic receptor alpha 2a (ADRA2A) agonist is ¥412.2 ($3.71) for...
21:26 , Jun 1, 2017 |  BC Extra  |  Politics & Policy

NIH seeks public-private partnerships to fight opioid crisis

In an article published in the New England Journal of Medicine and a blog post , NIH Director Francis Collins and National Institute on Drug Abuse (NIDA) Director Nora Volkow outlined a plan to speed...
19:09 , May 19, 2017 |  BC Week In Review  |  Company News

BioXcel creates subsidiary to develop cancer, neurology candidates

BioXcel Corp. (Branford, Conn.) launched new subsidiary BioXCel Therapeutics Inc. (BTI), which will use artificial intelligence-driven R&D to identify indications for candidates that demonstrated safety but not efficacy in Phase II testing or later. BTI's...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Clinical News

Intuniv guanfacine extended release regulatory update

The European Commission approved an MAA from Shire for once-daily Intuniv guanfacine extended release to treat ADHD in patients ages 6-17 for whom stimulants are not suitable, not tolerated or have been shown to be...